Press coverage about Humana (NYSE:HUM) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Humana earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave media stories about the insurance provider an impact score of 46.1416533829923 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Are Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or Humana Inc. (NYSE:HUM) Ready to Rumble? - FLBC News (flbcnews.com)
- Summit Health and Humana Inc, reach new network agreement (localdvm.com)
- [$$] Managed Care EPS Quality Improves (finance.yahoo.com)
- Amgen in Collaboration With Humana for Patients’ Benefit (finance.yahoo.com)
- Genuine Parts Co (GPC) and Humana Inc (HUM) Needle Moving on Volume - Evergreen Caller (evergreencaller.com)
Several research firms have commented on HUM. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $253.00 price objective for the company in a research report on Thursday, May 18th. BidaskClub downgraded shares of Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, June 13th. Citigroup Inc. started coverage on shares of Humana in a research note on Wednesday, June 28th. They issued a “buy” rating and a $275.00 target price on the stock. Credit Suisse Group reissued an “outperform” rating and issued a $260.00 target price (up previously from $250.00) on shares of Humana in a research note on Thursday, August 3rd. Finally, Deutsche Bank AG increased their target price on shares of Humana from $234.00 to $243.00 and gave the company a “hold” rating in a research note on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $244.35.
Humana (NYSE:HUM) opened at 247.28 on Friday. The stock has a market cap of $35.74 billion, a P/E ratio of 20.34 and a beta of 0.91. Humana has a 52-week low of $163.50 and a 52-week high of $255.27. The firm’s 50-day moving average is $241.05 and its 200-day moving average is $224.57.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.08 by $0.41. The company had revenue of $13.53 billion for the quarter, compared to analyst estimates of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same period in the prior year, the firm earned $2.30 earnings per share. Equities research analysts predict that Humana will post $11.55 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Tuesday, August 29th will be paid a dividend of $0.40 per share. The ex-dividend date is Thursday, September 28th. This represents a $1.60 dividend on an annualized basis and a yield of 0.65%. Humana’s dividend payout ratio (DPR) is presently 13.06%.
In related news, SVP Brian P. Leclaire sold 4,971 shares of the company’s stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the sale, the senior vice president now directly owns 14,258 shares in the company, valued at $3,421,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce D. Broussard sold 12,000 shares of the company’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $251.88, for a total transaction of $3,022,560.00. Following the sale, the chief executive officer now owns 80,086 shares in the company, valued at $20,172,061.68. The disclosure for this sale can be found here. Insiders have sold 41,406 shares of company stock worth $10,355,086 over the last quarter. Insiders own 0.80% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Humana (HUM) Earns Daily Media Impact Rating of 0.24” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/20/humana-hum-earns-daily-media-impact-rating-of-0-24.html.
About Humana
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
